USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Supply readiness follows months of manufacturing to ensure timely and ample supply
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Subscribe To Our Newsletter & Stay Updated